

FOR ANIMAL USE ONLY**BRAVECTO® SPOT-ON**

Reg. No. G4292 (Act 36/1947)

Namibia Reg. No. V19/18.3.10/1441 NSO**INDICATIONS**

For the treatment and prevention of tick, flea and mite infestations in dogs and cats.

Bravecto® Spot-On can be used as part of a treatment strategy for Flea Allergy Dermatitis (FAD). For the treatment of mange caused by *Demodex* spp. and *Sarcoptes scabiei* mites in dogs. For the treatment of *Otodectes* spp. mite infestations in dogs and cats.

In cats, **Bravecto® Spot-On** provides immediate and persistent flea and tick killing activity for 3 months.

In dogs, **Bravecto® Spot-On** provides immediate and persistent tick killing activity for 4 months and flea killing activity for 6 months. **Bravecto® Spot-On** is well tolerated in MDR1 dogs.

A single treatment prevents *Dipylidium caninum* transmission from infected fleas to susceptible dogs for 12 weeks.

COMPOSITION

Each 1 ml of **Bravecto® Spot-On** contains 280 mg fluralaner.

Each pipette delivers:

Miniature dogs:	112,5 mg fluralaner	Small cats:	112,5 mg fluralaner
Small dogs:	250 mg fluralaner	Medium cats:	250 mg fluralaner
Medium dogs:	500 mg fluralaner	Large cats:	500 mg fluralaner
Large dogs:	1 000 mg fluralaner		
Extra-large dogs:	1 400 mg fluralaner		

CLINICAL PHARMACOLOGY

Peak fluralaner concentrations are achieved between 7 and 42 days following topical administration and the elimination half-life ranges between 14 and 29 days. The bioavailability of fluralaner following oral and topical administration is approximately 25 %.

PHARMACODYNAMIC PROPERTIES

Fluralaner is an acaricide and insecticide. It is efficacious against ticks, fleas and mites.

Fluralaner is for systemic use and belongs to the class of isoxazoline-substituted benzamide derivatives.

Fluralaner is an inhibitor of parts of the arthropod nervous system. The mode of action of fluralaner is the antagonism of the ligand-gated chloride channels (gamma-aminobutyric acid (GABA)-receptor and glutamate-receptor).

CAUTION**STORAGE INSTRUCTIONS**

- Store at or below 30 °C in a cool, dry place.

- Store in the original package in order to protect from light.
- Do not use this veterinary medicinal product after the expiry date which is stated on the container label.

WARNINGS

- Handle with caution.
- For cats, safety has not been established during pregnancy and lactation. Use only according to the benefit/risk assessment by the responsible veterinarian.
- For dogs infected with tapeworm, we recommend a suitable tapeworm treatment be used.
- Do not use in the case of hypersensitivity to the active substance or to any of the excipients.
- Parasites need to start feeding on the host to become exposed to fluralaner; therefore, the risk of the transmission of parasite-borne diseases cannot be excluded but is reduced by the speed of efficacy.
- Care should be taken to avoid contact with the eyes of the animal.
- Do not use directly on skin lesions.
- Dogs can be washed/shampooed 3 days after treatment.
- Safety in puppies less than 8 weeks old and/or dogs weighing less than 2 kg has not been established.
- Safety in kittens less than 9 weeks old and/or cats weighing less than 1,2 kg has not been established.
- **Bravecto[®] Spot-On** should not be administered at intervals shorter than 8 weeks as the safety for shorter intervals has not been tested.
- Keep **Bravecto[®] Spot-On** in the original packaging until use.
- **Do not have contact with the animal or allow children to have contact with the animal until the application site is dry.**
- **Bravecto[®] Spot-On** is highly flammable. Keep away from heat, sparks, open flames or other sources of ignition.
- KEEP OUT OF REACH OF CHILDREN, UNINFORMED PERSONS AND ANIMALS.
- Although this remedy has been extensively tested under a large variety of conditions, failure thereof may ensue as a result of a wide range of reasons. If this is suspected, seek veterinary advice and notify the registration holder.

PRECAUTIONS

- For topical use only. Avoid oral ingestion.
- Do not eat, drink or smoke while handling the product.
- Wash hands thoroughly with soap and water immediately after the product has been used. If skin contact does occur, wash the affected area immediately with water. In some cases, water is not sufficient to remove the product spilled on the fingers. If a sticky residue persists on the skin after washing with water, then this can be removed using household items containing organic solvents [e.g., rubbing alcohol (ethanol, isopropyl alcohol) or nail polish remover (acetone)] applied gently with a swab.
- Do not store with food, drinks, medication or household products.
- Medicines should not be disposed of via wastewater or household waste but in accordance with the National Environmental Management: Waste Act, 2008 (Act No. 59 of 2008). These measures should help to protect the environment.

INTERACTIONS

Fluralaner is highly bound to plasma proteins and might compete with other highly bound drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) and the coumarin derivative warfarin. Incubation of fluralaner in the presence of carprofen or warfarin in dog plasma at maximum expected plasma concentrations did not reduce the protein binding of fluralaner, carprofen or warfarin.

During laboratory and clinical field testing, no interactions between **Bravecto® Spot-On** and routinely used veterinary medicinal products were observed.

ADVERSE REACTIONS

Commonly observed adverse reactions in clinical trials were mild and transient skin reactions at the application site (1,2 % of treated dogs and 2,2 % of treated cats).

Cat's skin reactions were such as erythema and pruritus (most likely due to a transient discomfort) or alopecia (secondary effect due to scratching or licking). As a result of transient discomfort shortly after administration, the following signs were observed: apathy/tremors/anorexia (0,9 % of treated cats) or vomiting/hypersalivation (0,4 % of treated cats). Based on post-registration experience, convulsions have very rarely been reported, (less than 1 in 10 000 animals treated).

Emesis, lethargy, inappetence, muscle tremors, ataxia and convulsions have been reported very rarely in spontaneous reports after the use of this product (less than 1 animal in 10 000 animals treated).

If you notice any serious effects or other effects not mentioned in this package leaflet, please inform your veterinarian.

DIRECTIONS FOR USE - USE ONLY AS DIRECTED

Bravecto® Spot-On should be administered in accordance with the following table (corresponding to a dose of between 25 and 56 mg fluralaner/kg body weight in dogs and between 40 and 94 mg fluralaner/kg body weight in cats within one weight band):

Weight of dog/cat (kg)	Pipette size to be used	Volume (mℓ)	Fluralaner (mg)
2 - 4,5	Miniature dogs	0,4	112,5
> 4,5 - 10	Small dogs	0,89	250
> 10 - 20	Medium dogs	1,79	500
> 20 - 40	Large dogs	3,57	1 000
> 40 - 56	Extra-large dogs	5,0	1 400
> 56	The appropriate combination of pipettes should be used.		
1,2 - 2,8	Small cats	0,4	112,5
> 2,8 - 6,25	Medium cats	0,89	250
> 6,25 - 12,5	Large cats	1,79	500

For optimal control of tick infestation, **Bravecto® Spot-On** should be administered every 3 months for cats and every 4 months for dogs.

For optimal control of flea infestation, **Bravecto® Spot-On** should be administered every 3 months for cats and every 6 months for dogs.

Within each weight range, a whole pipette must be used.


For dogs weighing more than 56 kg, use a combination of 2 pipettes that most closely matches the body weight.

For cats weighing more than 12,5 kg, use a combination of 2 pipettes that most closely matches the body weight.

Method of administration

Step 1

Open the sachet and remove the pipette immediately before use. The pipette should be held by the upper part of the tail base (crimped end) or by the upper rigid portion below the cap in an upright position (tip up) before opening it. The cap should be rotated clockwise or counterclockwise in one full turn. **The cap will stay on the pipette; it is not possible to remove it.** The pipette is open and ready for application when the breaking of the seal is felt.




Step 2

The dog/cat should be standing or lying with its back horizontally during application. Part the fur at the administration site. Place the pipette tip vertically against the skin between the shoulder blades of the dog or on the base of the skull of the cat.

Step 3

Dogs:

Squeeze the pipette gently and apply the entire contents directly to the dog's skin in one go (when volume is small) or several spots along the dog's dorsal line from the shoulder to the base of the tail. Avoid applying an excessive amount of solution at any one spot that could cause some of the solution to run or drip off the dog.



Cats

Squeeze the pipette gently and apply the entire contents directly to the cat's skin. The product should be applied in one spot (cats up to 6,25 kg body weight) at the base of the skull and in two spots on cats greater than 6,25 kg body weight. If 2 spots are required, apply both spots to the base of the skull. It is important to deliver the solution onto an area that cannot be easily licked by the cat. As cats are fastidious groomers, they may inadvertently ingest product if easily reached. Ingestion may cause adverse reactions and will remove product from the coat. If multiple cats are treated and may mutually groom, it is recommended that cats are separated while product dries.



OVERDOSE

Dogs

Safety was demonstrated in puppies aged between 8 and 9 weeks and weighing between 2,0 and 3,7 kg treated with overdoses of up to 5 times the maximum recommended dose on 3 occasions at shorter intervals than recommended (8-week intervals).

Safety was demonstrated in breeding, pregnant and lactating dogs treated with overdoses of up to 3 times the maximum recommended dose.

Bravecto® Spot-On was well tolerated in Collie dogs with a deficient multidrug-resistance-protein 1 (MDR1 -/-) following single oral administration at 3 times the recommended dose.

Cats

Safety was demonstrated in kittens aged between 9 and 13 weeks and weighing between 0,9 and 1,9 kg treated with overdoses of up to 5 times the maximum recommended dose on 3 occasions at shorter intervals than recommended (8-week intervals).

Oral uptake of **Bravecto® Spot-On** at the maximum recommended dose was, both locally and systemically, well tolerated in cats, apart from some self-limiting salivation and coughing immediately after administration.

In cats, safety has not been established during pregnancy and lactation.

EFFICACY

Bravecto® Spot-On was shown to be effective against ticks, fleas and mites.

It is a systemic insecticide and acaricide.

Cats: The product provides immediate and persistent flea and tick killing activity for 3 months.

Dogs: The product provides immediate and persistent tick killing activity for 4 months and flea killing activity for 6 months.

Ticks and fleas must attach to the host and commence feeding in order to be exposed to the active substance. The onset of effect is within 8 hours.

Bravecto® Spot-On is efficacious for the treatment of the following:

Ticks

Dogs: *Ixodes ricinus*, *Rhipicephalus sanguineus*, *Haemaphysalis elliptica* and *Dermacentor reticulatus*.

Cats: *Ixodes ricinus* and *Haemaphysalis elliptica*.

Directly after treatment, at least 90 % of ticks on the animals are killed within 8 hours. During the whole treatment interval, at least 90 % of ticks on the animals are killed within 12 hours.

Fleas

Dogs: *Ctenocephalides felis* and *Ctenocephalides canis*.

Cats: *Ctenocephalides felis*.

Directly after treatment, at least 95 % of fleas are killed within 8 hours.

During the whole treatment interval, at least 95 % of fleas on dogs are killed within 12 hours.

Control of flea infestations and Flea Allergy Dermatitis (FAD)

The flea life cycle is broken due to the rapid onset action and long-lasting efficacy against adult fleas on the animal and the absence of viable egg production. **Bravecto® Spot-On** effectively controls environmental flea populations in areas to which the animals have access.

Effect on immature stages

The product kills adult as well as juvenile ticks (larvae, nymphs). Newly emerged fleas on animals are killed before viable eggs are produced. An *in vitro* study also demonstrated that very low concentrations of fluralaner stop the production of viable eggs by fleas.

Mites

Dogs: Mange caused by *Demodex* spp. and *Sarcoptic* mange mites. For the treatment of *Otodectes* spp. mite infestations.

Cats: *Otodectes* spp.

PRESENTATION

Unit dose pipette made of laminated aluminium/polypropylene foil containing a colourless to yellowish solution, practically free from visible particles closed with cap and packed in a sachet. Each carton box contains 1 or 2 pipettes.

REGISTRATION HOLDER

Intervet South Africa (Pty) Ltd.

20 Spartan Road, Spartan

1619, RSA

Tel: +27 (0) 11 923 9300

E-mail: msdahza@msd.com

www.msd-animal-health.co.za

DATE OF PUBLICATION OF THIS PACKAGE INSERT

17 August 2023